ASPH Antibody (F-7): sc-365012

ASPH Antibody (F-7) is a mouse monoclonal IgG1 antibody that detects aspartyl/asparaginyl beta-hydroxylase (ASPH) in mouse, rat, and human samples through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). ASPH plays a crucial role in calcium homeostasis and is primarily located in the endoplasmic reticulum, where ASPH hydroxylates aspartate or asparagine residues in the epidermal growth factor-like domains of several proteins, utilizing iron as a cofactor. This post-translational modification is vital as ASPH influences protein stability, folding, and interactions, thereby impacting cellular signaling pathways and physiological processes. The ASPH gene encodes three distinct proteins—ASPH, Junctin, and Junctate (or Humbug)—which exhibit significant variation in their C-terminal domains and are expressed as five transcript variants, each with unique roles in calcium storage and release, hydroxylation capabilities, and tissue specificity. While all variants are present in skeletal muscle, ASPH expression in other tissues such as the heart, brain, pancreas, placenta, lung, liver, and kidney varies, highlighting ASPH importance in diverse biological contexts. Anti-ASPH antibody (F-7) is an essential tool for researchers investigating the functional implications of ASPH in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ASPH Antibody (F-7) References:

1. Mutations in ASPH cause facial dysmorphism, lens dislocation, anterior-segment abnormalities, and spontaneous filtering blebs, or Traboulsi syndrome.  |  Patel, N., et al. 2014. Am J Hum Genet. 94: 755-9. PMID: 24768550
2. Ethanol-Induced White Matter Atrophy Is Associated with Impaired Expression of Aspartyl-Asparaginyl-β-Hydroxylase (ASPH) and Notch Signaling in an Experimental Rat Model.  |  Tong, M., et al. 2017. J Drug Alcohol Res. 6: PMID: 29204305
3. MiR-200a inhibits cell proliferation and EMT by down-regulating the ASPH expression levels and affecting ERK and PI3K/Akt pathways in human hepatoma cells.  |  Yao, WF., et al. 2018. Am J Transl Res. 10: 1117-1130. PMID: 29736205
4. Hydroxylase Activity of ASPH Promotes Hepatocellular Carcinoma Metastasis Through Epithelial-to-Mesenchymal Transition Pathway.  |  Zou, Q., et al. 2018. EBioMedicine. 31: 287-298. PMID: 29764768
5. HMGA2 regulates circular RNA ASPH to promote tumor growth in lung adenocarcinoma.  |  Xu, L., et al. 2020. Cell Death Dis. 11: 593. PMID: 32719345
6. Circ_ASPH promotes cholangiocarcinoma growth and metastasis through the miR-581/ATP-binding cassette transporter G1 signaling pathway.  |  Xu, Y., et al. 2020. Cancer Commun (Lond). 40: 545-550. PMID: 32735059
7. Inhibition of circular RNA ASPH reduces the proliferation and promotes the apoptosis of hepatic stellate cells in hepatic fibrosis.  |  Meng, H., et al. 2023. Biochem Pharmacol. 210: 115451. PMID: 36758707
8. Overexpression of ASPH protein predicts poor outcomes in retroperitoneal liposarcoma patients.  |  Xiao, M., et al. 2023. Chin Med J (Engl). 136: 2113-2115. PMID: 36897757
9. Unusual catalytic strategy by non-heme Fe(ii)/2-oxoglutarate-dependent aspartyl hydroxylase AspH.  |  Krishnan, A., et al. 2024. Chem Sci. 15: 3466-3484. PMID: 38455014
10. Circ_0005699 Expedites ox-LDL-Triggered Endothelial Cell Injury via Targeting miR-384/ASPH Axis.  |  Cao, X., et al. 2024. Cardiovasc Toxicol. 24: 1067-1076. PMID: 38976139

The preferred ASPH antibody is ASPH Antibody (A-10): sc-271391.